Our laboratory focuses on the discovery genomic mechanisms of therapeutic sensitivity and resistance in breast cancers and some other types of carcinomas. We have interest in identifying ways to treat basal-like, triple negative, and inflammatory breast cancer using novel molecularly targeted therapeutics and combinations of these inhibitors to circumvent drug resistance.

Specifically, our ongoing projects include 1) Understanding the role of loss of the tumor suppressor DUSP4, a negative regulator of the MAPK pathway in breast cancer;2) Molecularly targeting tumors with amplification of JAK2 and neighboring genes; and 3) Discovering new ways to target the residual disease and micrometastatic component of TNBCs that do not respond completely to neoadjuvant (pre-surgical)chemotherapy.